Home » Research » Protein Glycosylation and Analysis

	Proteomics and Systems Biotechnology
	Cell Engineering and Gene Expression

Engineered mammalian cells are able to correctly fold and chemically modify recombinant human proteins used as therapeutics. As these modifications often affect the pharmacokinetic behaviour and bioactivity of therapeutic proteins in vivo, mammalian cell factories are now the major production system for the new generation of therapeutic recombinant proteins such as monoclonal antibodies. In the case of Mab’s, alterations in glycosylation can modulate bioactivity, and can contribute to significantly to the chemical heterogeneity of the recombinant protein population which make necessary analysis of the protein product labour-intensive and time-consuming.

We are developing bioprocess technologies to improve monoclonal antibody bioactivity in vivo, and an analytical platform to enable rapid and high-throughput characterization of monoclonal antibody molecular heterogeneity.

Researchers:

Jason Hodoniczky (jasonho@cheque.uq.edu.au)